Latest Information Update: 11 Feb 2008
At a glance
- Originator Hyland Immuno
- Class Anticoagulants
- Mechanism of Action Protein stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 22 Sep 1998 No-Development-Reported for Thrombosis in Austria (Injection)
- 25 Oct 1995 Preclinical development for Thrombosis in Austria (Injection)
- 16 Aug 1995 New profile